Drug Utilization Review Board
The DUR Board is responsible for the esbalishment of standards and criteria for the prospective and retrospective DUR programs. The DUR Board is charged with making recommendations for educational interventions to prescribers and pharmacists to identify and reduce overuse, abuse, fraud, and inappropriate or medically unnecessary care. Affiliated Computer Systems, Inc (ACS) assists the pharmacy program in conducting population-based educational interventions, approved by the DUR Board, for both medical prescribers and pharmacy providers.
Drugs or drug classes which are reviewed and found to be inappropriately utilized or have significant safety concerns are deemed candidates for prior authorization. These reviews are considered by the DUR Board and appropriate criteria for approval are determined by them, with input from medical and pharmacy providers, drug manufactures, and other experts.
| Members |
|
| Ernest Miller, DO, Chairman |
Kc Lovin, PA-C |
| Scott Brown, RPh, Co-Chairman |
Mary Nemeth Pyles, MSN, RN, CS |
| Greenbrier Almond, MD |
Karen Reed, RPh |
| Myra Chiang, MD |
Patrick Regan, PharmD |
| David Elliott, PharmD |
Kerry Stitzinger, RPh |
| Randall James, DO |
Chris Terpening, PharmD, PhD |
| Lester Labus, MD |
John Vanin, MD |